Synapse - David Straus

Results (356)

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay

Journal Article

Intlekofer, A. M.; Joffe, E.; Batlevi, C. L.; Hilden, P.; He, J.; Seshan, V. E.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, C. H.; Portlock, C.; more...
Blood Cancer Journal (2018)

Fulltext@MSK | Save

A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL

Journal Article

Sauter, C. S.; Matasar, M. J.; Schoder, H.; Devlin, S. M.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; more...
Blood (2018)

Fulltext@MSK | Save

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma

Journal Article

Connors, J. M.; Jurczak, W.; Straus, D. J.; Ansell, S. M.; Kim, W. S.; Gallamini, A.; Younes, A.; Alekseev, S.; Illés, Á.; Picardi, M.; more...
New England Journal of Medicine (2018)

Fulltext@MSK | Save

Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)

Meeting Abstract

Batlevi, C. L.; Hamlin, P. A.; Matasar, M. J.; Horwitz, S. M.; Gerecitano, J. F.; Moskowitz, C. H.; Straus, D. J.; Zelenetz, A. D.; Drullinsky, P.; Copeland, A.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Real world clinical and economic burden of patients with Hodgkin lymphoma (HL) who fail frontline (FL) therapy in the US

Meeting Abstract

Straus, D. J.; Bonafede, M.; Feliciano, J.; Cai, Q.; Noxon, V.; Princic, N.; Josephson, N.; Richhariya, A.
Blood (2017)

Fulltext@MSK | Save

A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Meeting Abstract

Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
Blood (2017)

Fulltext@MSK | Save

Genomic characteristics clinical phenotype and disease course of TP53 mutated diffuse large B cell lymphoma at diagnosis and relapse

Meeting Abstract

Joffe, E.; Batlevi, C. L.; Intlekofer, A. M.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Noy, A.; Straus, D. J.; Portlock, C. S.; Gerecitano, J.; more...
Blood (2017)

Fulltext@MSK | Save

Prognostic utility of serum TARC, MDC, IL10, and soluble CD163 levels with positron emission tomography (PET) response-adapted therapy for advanced-stage Hodgkin lymphoma (HL): A SWOG S0816 US Intergroup correlative study

Meeting Abstract

Hsi, E. D.; Li, H.; Nixon, A. B.; Evens, A. M.; Schoder, H.; Straus, D. J.; Bartlett, N. L.; Sweetenham, J. W.; Barr, P. M.; Fanale, M. A.; more...
Blood (2017)

Fulltext@MSK | Save

Brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A+AVD) as frontline therapy demonstrates superior modified progression-free survival versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma (HL): The phase 3 ECHELON-1 study